MedTrace Logo

Effect of EMST Systemic Inflammation and Oxidative Stress in Patients With Moderate OSAS

NCT05242406 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-08-14

No results posted yet for this study

Summary

It was aimed to investigate the effect of expiratory muscle strength training (EMST) applied at different intensities on systemic inflammation and oxidative stress in patients with moderate obstructive sleep apnea syndrome (OSAS). In the study, 32 male patients diagnosed with moderate OSAS will be included in the study. Participants will then be divided into 2 groups by block randomization. In the three-blind planned study; the first group will receive high-intensity %60 maximum expiratory pressure (MEP) EMST training, and the second group will be given low-intensity 30% of MEP, EMST training for 12 weeks. Disease-related symptoms, disease severity apnea-hypopnea index (AHI), oxidative stress index (OSI) and systemic inflammation level, exercise capacity, respiratory muscle strength, sleep quality, daytime sleepiness, and fatigue severity will be evaluated before and after the study.

Conditions

Interventions

OTHER

Expiratory muscle trainig

This exercise will be used to strengthen forced expiratory muscles.

Sponsors & Collaborators

  • Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital

    lead OTHER

Principal Investigators

  • Adem Çelik, MD · Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital

  • Sevim Kahraman Yaman, MD · Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital

  • Hüseyin Yaman, MD · Karadeniz Technical University

  • Nurel Erturk, MsC · Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital

  • Ebru Çalık Kütükçü, PhD · Hacettepe University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-04-01
Completion
2023-04-01

Countries

  • Turkey (Türkiye)

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05242406 on ClinicalTrials.gov